U.K. cost watchdogs turn away rare disease med Crysvita
U.K. cost watchdogs turn away rare disease med Crysvita Patients in the U.K. won’t have access to X-linked hypophosphatemia med Crysvita under a ruling by NICE. Source: Fierce Pharma U.K. […]
News & Press
Bristol-Myers’ Opdivo ushers in a new era as the first I-O therapy approved in China
Bristol-Myers’ Opdivo ushers in a new era as the first I-O therapy approved in China In a historic moment for China’s medical world, China’s Drug Administration on Friday approved Opdivo, […]
Chutes & Ladders—Alder poaches Juno executive for CEO
Chutes & Ladders—Alder poaches Juno executive for CEO Alder poaches Juno executive for CEO to prep for its migraine launch, Allergan brings in Abbott veteran after investors demand change, and […]
Bluebird preps E.U. filing for revamped thalassemia gene therapy
Bluebird preps E.U. filing for revamped thalassemia gene therapy With new data from a phase 1/2 trial of its LentiGlobin gene therapy in thalassemia in the bag, Bluebird Bio is […]
All-in-one CAR-T packages therapy and safety in one molecule
All-in-one CAR-T packages therapy and safety in one molecule French biotech Cellectis has devised a form of CAR-T that contains its therapeutic effects with a safeguard in a single molecule. […]